AM-Pharma B.V. announced that Professor Peter Pickkers, M.D., Ph.D., principal investigator of the Phase 3 REVIVAL study, will present data from the study at two upcoming scientific conferences.
AM-Pharma to Present Data From Phase 3 REVIVAL Study at Upcoming Scientific Conferences Read More »
QurAlis Corporation announced it has closed an oversubscribed $88 million Series B financing, bringing the total funds raised to $143.5 million.
Prestige Biopharma Limited, a Singapore-based biopharmaceutical company, has developed a first-in-class diagnostic kit for pancreatic cancer.
Oxford BioTherapeutics Ltd. announced it will reveal its new fully integrated ADC engine, combining its internationally recognised target discovery and ADC development capabilities, at the 13th Annual World ADC Conference being held in London, UK, from 13 to 16 March 2023.
Muchas personas tienen que ingerir probióticos, complejos vitamínicos y minerales por sufrir algún tipo de dolencia o enfermedad, realizar ejercicio físico intenso o padecer estrés, entre otras causas. Lo habitual es comprarlos en las farmacias, fundamentalmente do …
Nuevas bebidas probióticas con una bacteria de la aceituna Read More »
QIAGEN N.V. announced it has entered into a strategic partnership with Servier, a global pharmaceutical group, to develop a companion diagnostic test for TIBSOVO®, an isocitrate dehydrogenase-1 inhibitor indicated for the treatment of the blood cancer acute myeloid leukemia.
GenSight Biologics announced the publication of a peer-reviewed article in the renowned American Journal of Ophthalmology focusing on pooled safety data from the 5 clinical studies with lenadogene nolparvovec.
Biophytis SA announced that it presents the positive results of the phase 2-3 COVA study with Sarconeos in severe COVID-19 at the European Respiratory Society 2023 21st Lung Science Conference taking place in Estoril, Portugal, between the 9th and the 12th of March 2023.
Astellas Pharma Inc. and the Blood and Marrow Transplant Clinical Trials Network announced topline results from the Phase 3 MORPHO clinical trial evaluating gilteritinib as a maintenance therapy following allogeneic hematopoietic stem cell transplantation for patients with FMS-like tyrosine kinase 3 -internal tandem duplication mutated acute myeloid leukemia.
Astellas and BMT CTN Announce Topline Results from Phase 3 MORPHO Trial of Gilteritinib Read More »
Masimo announced the findings of a prospective study published in Pediatrics International in which Dr. Ya-Fei Liu and colleagues at Peking University First Hospital in Beijing evaluated the ability of noninvasive, continuous Masimo PVi®, alongside other dynamic parameters, to predict fluid responsiveness in children 1-3 years old who were undergoing major neurosurgery.
